FindMyKOL
Clinical trialNCT05333458RecruitingPhase 2Interventional

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

NCT05333458 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is recruiting participants. It studies Atezolizumab and Selinexor in Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma and 3 more conditions. The registry lists an enrollment of 27 participants at 13 sites in 1 country. The registry lists a start date of 29 Aug 2022 and a primary completion date of 1 May 2027. One of its registered investigators has a FindMyKOL profile.

SponsorNational Cancer Institute (NCI) →Enrollment27Advanced Alveolar Soft Part SarcomaAdvanced Soft Tissue SarcomaMetastatic Alveolar Soft Part SarcomaRefractory Alveolar Soft Part SarcomaUnresectable Alveolar Soft Part Sarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05333458
FieldValue
Registry IDNCT05333458
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorNational Cancer Institute (NCI)
Enrollment27
Registered sites13
Countries1
ConditionsAdvanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma and Unresectable Alveolar Soft Part Sarcoma
DrugsAtezolizumab and Selinexor
Start29 Aug 2022
Primary completion1 May 2027
Study completion1 May 2027
Last update posted18 Nov 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer. The usual approach is defined as care most people get for alveolar soft part sarcoma if they are not part of a clinical study, which includes treatment with radiation, kinase inhibitor drugs, immunotherapy drugs, or chemotherapy drugs. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may help keep cancer cells from growing and may kill them. Giving atezolizumab in combination with selinexor may help shrink tumors and stabilize the cancer in patients with alveolar soft part sarcoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States3 sites, 3 recruiting
  • Keck Medicine of Usc Koreatown

    Los Angeles

    Mark Agulnik
    Recruiting
  • Los Angeles General Medical Center

    Los Angeles

    Mark Agulnik
    Recruiting
  • Usc / Norris Comprehensive Cancer Center

    Los Angeles

    Mark Agulnik
    Recruiting
Connecticut, United States3 sites, 3 recruiting
  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford

    Philippos Apolinario Costa
    Recruiting
  • Yale University

    New Haven

    Philippos Apolinario Costa
    Recruiting
  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull

    Philippos Apolinario Costa
    Recruiting
District of Columbia, United States1 site, 1 recruiting
  • Medstar Georgetown University Hospital

    Washington D.C.

    Benjamin A. Weinberg
    Recruiting
Maryland, United States2 sites, 1 recruiting
  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda

    A P. Chen
    Recruiting
  • National Institutes of Health Clinical Center

    Bethesda

    Active, not recruiting
Ohio, United States1 site, 1 recruiting
  • Ohio State University Comprehensive Cancer Center

    Columbus

    David A. Liebner
    Recruiting
Oklahoma, United States1 site, 1 recruiting
  • University of Oklahoma Health Sciences Center

    Oklahoma City

    Minh Phan
    Recruiting
Pennsylvania, United States1 site, 1 recruiting
  • Upmc Hillman Cancer Center

    Pittsburgh

    Melissa A. Burgess
    Recruiting
Texas, United States1 site, 1 recruiting
  • Ut Md Anderson Cancer Center

    Houston

    Anthony P. Conley
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 1 site, 1 recruitingOH1Pennsylvania: 1 site, 1 recruitingPA1New JerseyNJConnecticut: 3 sites, 3 recruitingCT3California: 3 sites, 3 recruitingCA3NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 2 sites, 1 recruitingMD2DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahoma: 1 site, 1 recruitingOK1LouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 site, 1 recruitingTX1FloridaFLDistrict of Columbia: 1 site, 1 recruitingDC1
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05333458

Each answer restates registry values shown on this page.

What is NCT05333458?

NCT05333458 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Atezolizumab and Selinexor in Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma and 3 more conditions.

Is NCT05333458 recruiting?

As of 21 Nov 2026, it is recruiting participants. 12 of its 13 sites list their own status as recruiting.

Who leads NCT05333458?

The registry names A P Chen (principal investigator, National Cancer Institute LAO) as the overall official.

Where does NCT05333458 run?

The registry lists 13 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05333458 study?

The registered drug and biological interventions are Atezolizumab and Selinexor.

When is NCT05333458 expected to complete?

The registry lists a primary completion date of 1 May 2027 and a study completion date of 1 May 2027. The sponsor last updated the record on 18 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.